AbbVie Inc. diskutieren
AbbVie Inc.
WKN: A1J84E / Symbol: ABBV / Name: AbbVie / Aktie / Pharmazeutika / Large Cap /
184,80 €
-0,96 %
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at Citigroup Inc. from $226.00 to $215.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at JPMorgan Chase & Co. from $210.00 to $200.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $205.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Wells Fargo & Company to $195.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Piper Sandler from $212.00 to $220.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its "overweight" rating re-affirmed by analysts at Piper Sandler Companies. They now have a $220.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at Truist Financial Co. from $215.00 to $211.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at Citigroup Inc. from $215.00 to $205.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Guggenheim from $212.00 to $214.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at BMO Capital Markets from $208.00 to $215.00. They now have an "outperform" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $220.00 price target on the stock, up previously from $218.00.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Morgan Stanley from $224.00 to $239.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Wells Fargo & Company from $195.00 to $210.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Truist Financial Co. from $211.00 to $217.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Citigroup Inc. from $205.00 to $215.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Wells Fargo & Company from $210.00 to $240.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Morgan Stanley from $239.00 to $241.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $214.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie Inc. (NYSE: ABBV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $210.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Cushman & Wakefield PLC diskutieren